Please assess the completion status of the following clinical trial:

Trial Title: Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed recurrent adenocarcinoma of the prostate within the past year~  * No transitional cell, small cell, or squamous cell carcinoma of the prostate~ * Local recurrence~* Disease recurred ≥ 18 months after completion of prior external beam radiotherapy (EBRT) for stage T1-T2b, N0/X, M0 disease~  * Biochemical failure as defined by the Phoenix definition (rise in PSA by 2 ng/mL or more above the nadir PSA)~    * PSA ≥ 0.3 ng/mL to \< 20 ng/mL measured within the past 30 days~ * Pre-EBRT PSA \< 50 ng/mL~ * Prior locally recurrent hormone-refractory disease allowed~* American Urologic Association Obstructive Symptom Index Score ≤ 24~* No known standard therapy that is potentially curative or definitely capable of extending life expectancy~* No evidence of or history of metastatic adenocarcinoma of the prostate~  * Negative radiographic metastatic work-up including whole-body radionuclide bone scan, CT and/or MR scan of the pelvis and abdomen, and chest x-ray~    * Patients with suspicious areas on conventional imaging studies are eligible provided they are biopsy negative~ * No known CNS metastases~* No prostate size \> 140 cc~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 12 weeks~* ANC ≥ 1,500/μL~* Platelet count ≥ 100,000/μL~* Hemoglobin ≥ 8.5 g/dL~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* INR ≤ 1.4 times ULN~* Creatinine ≤ 1.5 times ULN~* Thyroid-stimulating hormone 0.3-5.0 uIU/mL and free thyroxine 0.8-1.87 ng/dL~* Willing to provide biologic specimens and participate in imaging studies as required~* Willing to maintain a low-iodine diet for 12 days~  * Starting 7 days prior to study virus injection continuing until after the iodine I 131 radioiodine therapy on day 5~* No more than 1 of the following renal/genitourinary toxicities:~  * Bladder spasms~ * Dysuria (painful urination)~ * Genitourinary fistula~ * Hemoglobinuria~ * Incontinence~ * Operative injury to bladder and/or ureter~ * Proteinuria~ * Renal failure~ * Uretal obstruction~ * Urinary frequency/urgency~ * Urinary retention~ * Urine color change (not related to other dietary or physiologic cause \[e.g., bilirubin, concentrated urine, or hematuria\])~ * Other renal/genitourinary toxicities~* No urinary tract infection within 72 hours prior to registration~* No pubic arch interference study demonstrating unacceptable prostate access by the transperineal approach~* No absence of rectum or other anatomic features that would preclude transperineal needle insertion into the prostate~* No coagulopathy that contraindicates transperineal and intraprostatic needle insertion~* No other cancer within the past 2 years, except for squamous cell and basal cell skin cancers~* No uncontrolled infection or fever \> 100°F~* No known cardiac disease~* No seizure disorder~* No documented history of HIV positivity or other acquired immunodeficiency disorder or congenital immunodeficiency disorder~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from acute, reversible effects of prior chemotherapy~* Androgen-deprivation therapy (if applicable) initiated more than 3 months prior to registration~  * Patients who have undergone bilateral orchiectomy are eligible if they meet all other criteria~* At least 6 weeks since prior bicalutamide, nilutamide, or oral or intravenous iodinated contrast~* At least 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas), immunotherapy, biologic therapy, or other experimental drugs~* At least 4 weeks since prior and no concurrent anti-androgens (e.g., flutamide, estrogens, ketoconazole, PC-SPES, finasteride, or megestrol acetate)~* At least 2 weeks since prior and no concurrent exogenous corticosteroids~  * Patients clinically proven to require maintenance steroids allowed provided there has been no change in their dose within the past 6 weeks~* No antibiotic therapy within the past 72 hours~* No prior organ transplantation~* No prior salvage prostatectomy or brachytherapy~* No other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational~* No concurrent prophylactic use of colony-stimulating factors~* No concurrent enrollment in any other study involving a pharmacologic agent (drugs, biologics, immunotherapy approaches, gene therapy) whether for symptom control or therapeutic intent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues